Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 15;13(5):1623-1639.
eCollection 2023.

Enhancement of treatment efficacy of hepatic tumours using Trans-arterial-chemoembolization

Krishna Pillai  1 , Kevin Ke  1 , Ahmed Mekkawy  1 , Javed Akhter  1 , David L Morris  1
Affiliations
Review

Enhancement of treatment efficacy of hepatic tumours using Trans-arterial-chemoembolization

Krishna Pillai et al. Am J Cancer Res. .

Abstract

This review article examines the basic principle underlying trans-arterial chemoembolization (TACE) used for treating unrespectable liver cancer with discussion on the barriers that are present for efficient drug delivery with suggestions on methods that may be used to overcome these barriers and hence enhance the efficacy of the technique. Current drugs used with TACE along with inhibitors of neovascularisation are briefly discussed. It also compares the conventional method of chemoembolization with TACE and rationalizes why there is not much of a difference between the two methods on treatment efficacy. Further it also suggests alternative methods of drug delivery that may be used instead of TACE. Additionally, it discusses the disadvantages on using non degradable microspheres with recommendations for degradable microspheres within 24 hours to overcome rebound neovascularisation owing to hypoxia. Finally, the review examines some of the biomarkers that are used to assess treatment efficacy with indication that non-invasive and sensitive biomarkers should be identified for routine screening and early detection. The review concludes that, if the current barriers present in TACE can be overcome along with the use of degradable microspheres and efficient biomarkers for monitoring efficacy, then a more robust treatment would emerge that may even serve as a cure.

Keywords: Sorafenib; Transarterial-chemoembolization; biomarkers; hepatic cellular carcinoma; microspheres; neo-vascularisation.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
It is a diagrammatic representation of enhanced clearance with build-up of Intra-tumoral fluid pressure. Mark 1 Indicates direction of blood flow in the blood vessels; Mark 2 Direction of drug diffusion; Mark 3 drugs escaping to newly formed blood capillaries. ITFP = Intra-tumoral fluid pressure.
Figure 2
Figure 2
Barriers to drug penetration and efficacy with possible methods to surmount them to increase the efficacy of TACE. ECM: extracellular matrix; HCC: Hepatic cellular carcinoma; TACE: trans-arterial-chemoembolization; VEGF: vascular epidermal growth factors.
Figure 3
Figure 3
Demonstrates the principals involved in intra-tumoral drug delivery system. ITFP: intratumoural fluid pressure.
Figure 4
Figure 4
Shows some of the common biomarkers that are detected in HCC for diagnostic and therapeutic purpose.
Figure 5
Figure 5
TACE as an ideal treatment for non-resectable HCC.
See this image and copyright information in PMC

References

    1. Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, Hamadeh RR, Moore A, Werdecker A, Gessner BD, Te Ao B, McMahon B, Karimkhani C, Yu C, Cooke GS, Schwebel DC, Carpenter DO, Pereira DM, Nash D, Kazi DS, De Leo D, Plass D, Ukwaja KN, Thurston GD, Yun Jin K, Simard EP, Mills E, Park EK, Catalá-López F, deVeber G, Gotay C, Khan G, Hosgood HD 3rd, Santos IS, Leasher JL, Singh J, Leigh J, Jonas JB, Sanabria J, Beardsley J, Jacobsen KH, Takahashi K, Franklin RC, Ronfani L, Montico M, Naldi L, Tonelli M, Geleijnse J, Petzold M, Shrime MG, Younis M, Yonemoto N, Breitborde N, Yip P, Pourmalek F, Lotufo PA, Esteghamati A, Hankey GJ, Ali R, Lunevicius R, Malekzadeh R, Dellavalle R, Weintraub R, Lucas R, Hay R, Rojas-Rueda D, Westerman R, Sepanlou SG, Nolte S, Patten S, Weichenthal S, Abera SF, Fereshtehnejad SM, Shiue I, Driscoll T, Vasankari T, Alsharif U, Rahimi-Movaghar V, Vlassov VV, Marcenes WS, Mekonnen W, Melaku YA, Yano Y, Artaman A, Campos I, MacLachlan J, Mueller U, Kim D, Trillini M, Eshrati B, Williams HC, Shibuya K, Dandona R, Murthy K, Cowie B, Amare AT, Antonio CA, Castañeda-Orjuela C, van Gool CH, Violante F, Oh IH, Deribe K, Soreide K, Knibbs L, Kereselidze M, Green M, Cardenas R, Roy N, Tillmann T, Li Y, Krueger H, Monasta L, Dey S, Sheikhbahaei S, Hafezi-Nejad N, Kumar GA, Sreeramareddy CT, Dandona L, Wang H, Vollset SE, Mokdad A, Salomon JA, Lozano R, Vos T, Forouzanfar M, Lopez A, Murray C, Naghavi M. The global burden of cancer 2013. JAMA Oncol. 2015;1:505. - PMC - PubMed
    1. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37:S88–S94. - PubMed
    1. Venook AP, Papandreou C, Furuse J, De Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Suppl 4):5–13. - PubMed
    1. Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2010;24:899–919. - PMC - PubMed
    1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127. - PubMed

LinkOut - more resources